INTRODUCTION
Abnormal carbohydrate metabolism in renal disease of diverse origin has been appreciated for over 60 yr, yet the mechanisms underlying this glucose intolerance remain unsettled. Decreased sensitivity of peripheral tissues to insulin seems well established. The results of forearm perfusion studies (1) (2) (3) , the presence of elevated fasting immunoreactive insulin levels in uremia (4) (5) (6) (7) (8) (9) , and the delayed and diminished glucose response after exogenous insulin (5, (9) (10) (11) (12) (13) (14) (15) and tolbutamide (4, 9, 11, (14) (15) (16) indicate the presence of insulin resistance in the majority of patients with chronic renal failure. In contrast, conflicting reports have appeared on the plasma insulin response to intravenous and oral glucose in uremia. Although all investigators have found the late insulin response to be elevated (4-9, 11, 17, 18) , the early insulin response has been reported to be normal (4, 5, 7, 17) , increased (6, 9) or decreased (11, 18) . In a recent review (19) , we suggested that these apparent discrepancies could be resolved by postulating a balance between the effects of uremia on peripheral insulin antagonism and on pancreatic insulin secretion. If insulin synthesis and release were not impaired, glucose tolerance might be expected to remain normal despite peripheral insulin antagonism at the expense of hypersecretion of insulin. If, however, insulin antagonism were especially severe or if significant inhibition of insulin secretion were to be superimposed on a state of peripheral insulin resistance, glucose intolerance would result.
With the glucose clamp technique we have examined the relative contributions of impaired insulin secretion and tissue insensitivity to insulin in the genesis of uremia-induced carbohydrate intolerance. METHODS 10 ambulatory volunteers with chronic renal disease ranging in age from 24 to 49 yr were studied (Table I ). There were six men and four women and all were within 20% of their desirable body weight.1 All subjects were free of gastro-'The middle of the weight range for subjects of medium frame from the 1959 Metropolitan Life Insurance Company table for desirable weight was used.
intestinal symptoms and were consuming a weight maintaining diet containing at least 200 g of carbohydrate per day for 3 days before study. Two patients (nos. 5 and 7) were on moderate protein restriction (40 g/day); for the 5 days immediately before study, however, the protein restriction was discontinued. There was no family history of diabetes mellitus; clinical evidence of diabetic retinopathy and neuropathy were absent; renal histology revealed no lesions suggestive of diabetic nephropathy. Liver function tests (serum glutamic-oxaloacetic transaminase, serum glutamicpyruvic transaminase, lactate dehydrogenase, alkaline phosphatase, bilirubin) were normal in all and there was no evidence ofother endocrinologic disorders. 9 of 10 were on no medication for at least 2 wk before study. One subject (no. 6) was taking guanethidine in a dose of 10 mg/day, except on the morning of study. Pertinent clinical data for each subject are outlined in Table I Eight normal weight (obesity index = 0.92-1.20) male volunteers ranging in age from 22 to 47 yr served as controls for the hyperglycemic clamp studies.
Euglycemic clamp. A prime plus continuous infusion of crystalline porcine insulin (Eli Lilly Co., Indianapolis, Ind.) was administered to attain constant hyperinsulinemia (21) . The priming dose was administered in a logarithmically falling manner over 10 min at which time the continuous insulin infusion was begun. The total amount of insulin infused during the priming period was twice that infused during subsequent 10-min intervals. The continuous insulin infusion (40 mU/M2 surface area per min) was maintained for 70 min.3 All experiments were continued for an addi2Abbreviations used in this paper: I, plasma insulin level; M, glucose metabolism; MCR, metabolic clearance rate. 3 In patients 2, 9, and 10 the continuous infusion was extended to 120 min. tional 40 min after the infusion was stopped. To prevent insulin absorption to glassware and to the plastic infusion apparatus, infusates were prepared with the addition of 2 ml of the subject's whole blood per 50 ml of infusate. Hypoglycemia with its attendant counter-regulatory responses was prevented by the glucose-clamp technique which was used to maintain each subject at his own basal arterial blood glucose concentration during and after insulin administration. The initial glucose infusion rate was 2.0 mg/kg body wt per min and was started 4 min after the insulin infusion was begun. At 10 min the glucose infusion was increased to 2.5-3.0 mg/kg per min; these doses were empirically determined. The first servo-correction was made at 14.5 min. Under the condition ofconstant euglycemia all of the glucose infused (M) is metabolized and is thus a measure of the body's sensitivity to insulin.
During the euglycemia clamp in patients 9 and 10, the effect of insulin on hepatic glucose production was examined with tritiated glucose labeled in the "3" position ([3H]glucose). For Methods for the determination of plasma immunoreactive insulin (21) and glucose specific activity (25) have previously been published. All serum chemistries (Table I) were determined by the routine clinical chemistry laboratory. All dataare presented as the meantSEM. Before participation the purpose and potential risks of the study were explained to all subjects and informed voluntary consent was obtained.
RESULTS
Oral and intravenous glucose tolerance tests (Table  II) . Oral glucose tolerance was poor in three of the subjects predialysis (nos. 2, 5, and 8), and each of these improved postdialysis to the normal range (20) . Only two of the subjects had grossly abnormal performances on the intravenous glucose tolerance test. Both of these subjects improved postdialysis but performance remained poor.
Hyperglycemic clamp. Predialysis the fasting blood glucose concentration averaged 114+3 mg/dl. During the period of sustained hyperglycemia the mean glucose concentration of the eight subjects was 238+4 mg/dl. In the postdialysis studies the fasting blood glucose and steady-state hyperglycemic levels averaged 105±2 and 229±3 mg/dl, respectively. The stability of the blood glucose concentration during the period of hyperglycemia is reflected by the coefficient of variation which averaged 2.7+0.3 during the predialysis studies and 3.2±0.3 during the postdialysis studies.
The amount of glucose metabolized (M) during the 120-min period of sustained hyperglycemia increased in all eight subjects from an average of 4 (Table III) . Predialysis seven of eight subjects were below the normal control range (Fig. 1) . After dialysis, six of eight subjects fell within the normal range.
The plasma insulin concentration in response to the sustained hyperglycemia was biphasic with an early burst in insulin within the first 6 min followed by a gradually increasing phase of insulin release that lasted until the end of the study (Fig. 2) . There was no difference in the early insulin response (0-10 min) between uremic subjects pre-and postdialysis and control subjects. After the initial peak, insulin values in uremics were significantly greater than controls (P < 0.01). After dialysis the late plasma insulin responses returned toward control values but the difference between pre-and post-dialysis values was not statistically significant. The fasting plasma insulin concentration was elevated predialysis (14.8±1. 4 ,tU/ml) and remained unchanged postdialysis (15.1+1.3 ,uU/ ml). Both the pre-and postdialysis values were greater than controls (P < 0.02).
Tissue sensitivity to insulin (M/I ratio) postdialysis increased in all eight subjects by an average of 80+25% (Table III) . All but subject no. 1 demonstrated >30% increase in insulin sensitivity. In this patient the improvement in glucose metabolism (M) was entirely accounted for by an increase in insulin secretion (48%) postdialysis. glucose metabolized (M) increased significantly in all eight subjects postdialysis, yet insulin response diminished slightly. Consequently, the M/I ratio increased by an average of 80%, representing a marked improvement in the body's sensitivity to insulin. Euglycemi ic clamp. The 10 uremic patients were studied pre-and postdialysis and were compared to eight age-and weight-matched normal control subjects. The insulin infusion resulted in a steady-state plasma insulin level (20-80 min) that averaged 110+4 and 91±6 ,uU/ml pre-and postdialysis. The corresponding value in the control subjects was 87±4 ,U/ml. Predialysis levels were significantly higher than both postdialysis (P < 0.005, paired analysis) and control (P < 0.005) levels. The stability of the plasma insulin concentration during the plateau period was essentially the same pre-and postdialysis and in the control group; coefficients of variation averaged 10.5±+1.0, 9.6+0.8, and 10±1.6, respectively. The mean plasma insulin concentrations over the entire 120-min period are presented in Table IV . The higher levels in subjects 2, 9, and 10 reflect the fact that the insulin infusion period was 120 min in these subjects, but was 80 min in the other subjects.
The MCR of insulin (insulin infusion rate divided by the increase above basal in the 20-80-min insulin concentration) increased by 29% postdialysis (P < 0.005, Table IV ). The MCR of the control group was 527+26. Thus, on the average, the uremic patients predialysis had a somewhat lower MCR than controls; the increase in MCR postdialysis led to an average value somewhat higher than the control group, but neither of these differences were statistically significant.
The blood glucose concentration was maintained at a constant level during the period of hyperinsulinemia. The mean coefficients of variation pre-and postdialysis were 3.3+0.3 and 3.6+0.3%, respectively. The corresponding value in the control subjects was 4.8+±0.4%. postdialysis from 3.37+0.36 to 3.99+0.27 mg/kg per min (P < 0.05, Table IV ). The M of the control group was 4.24+0.22, a value significantly greater than the uremics predialysis (P < 0.05) but not significantly different from the uremics postdialysis. After dialysis tissue sensitivity to insulin (M/I) increased from 3.56+0.33 to 5.23+0.48 (in units of mg/kg per min per AU/ml x 100). In paired analysis the increase in sensitivity was statistically significant (P < 0.01, Table IV ). Tissue sensitivity to insulin in the control group was 6.00±0.41. Thus, the uremics predialysis were significantly less sensitive to insulin than normal (P < 0.005), and dialysis on the average corrected this defect.
In patients 9 and 10 basal glucose production averaged 3.06 mg/kg per min predialysis and fell to 0.50 mg/kg per min during the euglycemic clamp. After dialysis basal glucose production was unchanged and a similar decline was observed after insulin (Table V) .
DISCUSSION
Despite numerous investigations into the mechanisms underlying the glucose intolerance of uremia, a clear consensus has not emerged. The usual techniques for assessing glucose tolerance, oral and intravenous glucose administration, clearly demonstrate the intolerance; however, even with the monitoring of plasma insulin responses and use of the insulin/glucose ratio, definition of the mechanism(s) underlying the glucose intolerance is unclear. The glucose clamp technique offers a number of advantages over these clinical tests:
(a) The hyperglycemic stimulus to the beta cell is controlled; thus, repeated studies (pre-and postdialysis) of beta cell sensitivity can be accurately interpreted and compared to normal control subjects receiving an identical hyperglycemic stimulus.
(b) In the clinical tests the complex glucose-insulin feedback interaction (plasma glucose concentration stimulates insulin release which in turn lowers the glucose concentration) prohibits quantification of the sensitivity of body tissues to insulin; the glucose clamp, by controlling one of these variables and by providing a measure of glucose metabolized, overcomes this problem.
(c) The euglycemic clamp technique offers advantages over the previously used technique for assessing "insulin sensitivity", the intravenous insulin tolerance test. By maintaining the basal glucose level after insulin administration, not only is the discomfort and potential hazard of hypoglycemic reactions prevented, but the complex neuro-endocrine response to hypoglycemia does not occur. The test thus provides a purer estimate of sensitivity to insulin. The establishment of a steady-state level of plasma insulin concentration also allows the calculation of the metabolic clearance rate of insulin.
(d) The hyperglycemic and euglycemic clamps provide independent tests of the sensitivity of the body to endogenously released and to exogenously administered insulin.
The role of impaired insulin secretion in the genesis of uremia-induced glucose intolerance has been the subject of many conflicting reports (19) . The plasma concentrations of insulin achieved during the later phases of both the oral and intravenous glucose tolerance test have been reported to be elevated. However, these studies were not designed to determine whether the increased levels of insulin were the consequence of (a) true hypersecretion of insulin, (b) relative hypersecretion secondary to the higher glucose levels late in the test, (c) the prolonged halflife of insulin that occurs in uremia, or (d) a combination of these. The early phase of insulin release has been even less well characterized with various investigators reporting increased (6, 9) , normal (4, 5, 7, 17) , or decreased (11, 18) insulin secretion. Attempts to resolve this issue by utilizing the insulin/glucose ratio have been equally conflicting (19) .
Under the condition of sustained, constant hyperglycemia, the plasma insulin response in uremic subjects was biphasic with an early burst of insulin followed by a gradually increasing phase of insulin release. This pattern has been previously described in man (26) (27) (28) and animal (29, 30) . While the pattern of plasma insulin response to hyperglycemia in uremic patients predialysis was normal, the level of response was greater than normal afater the initial insulin peak. After dialysis the insulin response was reduced by 1 1% but this change was not statistically significant. Since the MCR of insulin increased after dialysis, this change in itself would cause a decrease in the plasma insulin level. It is of interest, therefore, to examine the quantitative aspects of the relation between plasma insulin level and MCR. This can be done by estimating the systemic (or posthepatic) delivery rate of insulin during the 2-h hyperglycemic period. The systemic delivery rate can be approximated from the product of the MCR and the mean plasma insulin concentration ( (Table III) is the result of a small increase (14%) in systemic insulin delivery rate (Table VI) in conjunction with a significant increase (32%) in the MCR (Table IV) .
It should also be noted that the increase in MCR of insulin after dialysis occurred without change in renal function. Similar findings have been reported by Hampers et al (31) in anephric patients. These results suggest that inhibition of some insulin-degrading organ system other than the kidney occurs in uremia. Since the liver normally degrades 50% or more of the insulin released by the pancreas (32, 33) , hyperinsulinemia ( Fig. 2) could be explained by a defect in hepatic degradation. In support of this hypothesis Wildberger et al. (34) found that liver extracts of nephrotic rats inactivate less insulin than controls.
The individual variability in the change in beta cell response to glucose after dialysis is best understood when viewed in relation to the changes in tissue sensitivity to insulin. After dialysis a significant improvement in tissue sensitivity to insulin (M/I) occurred in seven of eight subjects studied with the hyperglycemic clamp (range = 33-230%). These data suggest that the dominant factor contributing to the glucose intolerance of uremia is tissue resistance to the action of insulin. As dialysis corrects this insulin resistance, glucose tolerance improves despite either no change (patient 4) or even a decrease (patients 2, 5, 7, and 8) in beta cell sensitivity to hyperglycemia (Table III) . FIGURE 4 Correlation between the changes in beta cell sensitivity to glucose and log tissue sensitivity to insulin postdialysis.
However, it is clear that in some subjects a defect in insulin response contributes to the glucose intolerance. In patient 1, glucose metabolism improved by 50%, yet tissue sensitivity to insulin improved by only 2% (Table III) . Here the improvement in glucose tolerance after dialysis was entirely attributable to an increase in insulin response. In two other subjects (nos. 3 and 6), both an increased insulin response and enhanced tissue sensitivity contributed to the improvement in glucose tolerance after dialysis. The change in tissue sensitivity to insulin after dialysis is strongly inversely correlated with the log change in beta cell sensitivity to glucose (Fig. 4) (r = -0.920; P < 0.001). Those individuals who showed the most improvement in tissue sensitivity to insulin (left of dashed line) actually decreased their plasma insulin response to hyperglycemia; those whose improvement in tissue sensitivity was more modest (right of dashed line) showed increases in beta cell response.
Because all 10 subjects received euglycemic clamp studies pre-and postdialysis, independent measures of sensitivity to insulin are available and the results of the estimates on the two types of clamps can be compared. In the euglycemic studies, improvement in sensitivity occurred in 9 of 10 subjects and averaged 57%; this value agrees well with the mean improvement seen in the hyperglycemic clamp, 80%. A comparison of the estimates of improvement after dialysis in tissue sensitivity to insulin with the two types of clamps can be seen in Fig. 5 . In general, the improvements in insulin sensitivity in individual subjects by the two techniques agree well. This agreement between the two clamps was tested for statistical significance by correlating the logarithms of the percent change in M/I postdialysis for the two clamps; the r value of 0.874 is significant at P = 0.01. Insulin resistance in uremia could result from decreased tissue uptake of glucose or augmented hepatic glucose production, which is incompletely suppressed by insulin. The results of the glucose turnover studies in patients 9 and 10 suggest that the liver in uremia is normally responsive to insulin and that the improvement in tissue sensitivity observed after dialysis is the result of enhanced glucose uptake by peripheral tissues. These results are in agreement with a recent report by Mondon et al. (35) who observed normal suppression ofhepatic glucose production by insulin in uremic rats and impairment of glucose uptake by the perfused hindlimb.
Numerous factors have been implicated in the pathogenesis of the carbohydrate intolerance of uremia and these have been the subject of a recent review (19) . None of our patients had significant hypokalemia, hypermagnesemia, or acidosis (Table I ). There was no correlation between the type of renal disease and the presence of glucose intolerance. All subjects had long-standing, severe renal insufficiency. All were free of gastrointestinal symptoms, were on weight maintaining diets, and manifested no clinical evidence of malnutrition. Mild hypoalbuminemia (average serum albumin = 3.2±0.2 g/dl) was present predialysis. However, glucose intolerance improved postdialysis without change in serum albumin (3.4±0.2 g/dl). Elevated plasma levels of growth hormone (5, 8, 9, (36) (37) (38) (39) and glucagon (40, 41) have been implicated in the glucose intolerance ofuremia. Glucagon was not evaluated in the present study, but hepatic glucose production was normally suppressed by insulin in the two patients in whom it was examined. We were able to correct the glucose intolerance despite persistently elevated growth hormone levels (unpublished observations).
